NCT03606499View on ClinicalTrials.gov

Real-world Effectiveness of Ustekinumab in Participants Suffering From Inflammatory Bowel Disease (Crohn's Disease or Ulcerative Colitis) With Extra-intestinal Manifestations or Immune-mediated Inflammatory Diseases

CompletedOBSERVATIONAL

Enrollment

111

Participants

Timeline

Start Date

September 26, 2018

Primary Completion Date

March 17, 2023

Study Completion Date

March 17, 2023

Conditions

Crohn DiseaseColitis, Ulcerative

Interventions

DRUG

Ustekinumab

No study treatment will be administered as a part of this study. Participants who are initiating the treatment with ustekinumab, will be observed according to standard clinical practice.

Trial Locations (1)

54511

CHU de Nancy - Hopital de Brabois, Vandœuvre-lès-Nancy

All Listed Sponsors

lead

Janssen Cilag S.A.S.

INDUSTRY

NCT03606499 - Real-world Effectiveness of Ustekinumab in Participants Suffering From Inflammatory Bowel Disease (Crohn's Disease or Ulcerative Colitis) With Extra-intestinal Manifestations or Immune-mediated Inflammatory Diseases | Biotech Hunter | Biotech Hunter